BackEyePoint Pharmaceuticals Overview
EyePoint Pharmaceuticals Inc

EyePoint Pharmaceuticals Target Price

See EyePoint Pharmaceuticals's analyst price targets ($35) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$5.47

Average Target Price

$35.33545.9% upside

3 analysts in the last 4 months

High: $40 | Low: $27

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-06H.C. Wainwright$27393.6% upsideOpen
2026-07-29Mizuho SecuritiesGraig Suvannavejh$39613% upsideOpen
2026-07-15Stifel NicolausAnnabel Samimy$40631.3% upsideOpen
2026-02-19Mizuho Securities$36558.1% upsideOpen
2026-02-05RBC CapitalLisa Walter$39613% upsideOpen
2025-10-29Mizuho SecuritiesGraig Suvannavejh$33503.3% upsideOpen
2025-10-20Mizuho SecuritiesGraig Suvannavejh$28411.9% upsideOpen
2024-11-11H.C. WainwrightYi Chen$22302.2% upsideOpen
2024-05-13H.C. WainwrightYi Chen$30448.4% upsideOpen
2024-05-07Mizuho SecuritiesGraig Suvannavejh$30448.4% upsideOpen
2022-08-04H.C. Wainwright$25357% upsideOpen

EyePoint Pharmaceuticals (EYPT) FAQ

EyePoint Pharmaceuticals's target price stands at $35. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

The Street's average target of $35 for EYPT implies 545.9% upside versus today's price ($5.47). Positive implied upside usually reflects optimism on growth or margins, while a large downside can signal valuation or fundamental concerns. Check recommendation mix and recent target changes for more context.

The history chart shows how EyePoint Pharmaceuticals's target price evolved across reporting periods, while the comparison chart places EYPT next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, target price is commonly used to spot outliers. EyePoint Pharmaceuticals's reading of $35 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.